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Article abstract  
DNA lesions encountered by replicative polymerases threaten genome stability and cell cycle 
progression. Here we report the identification of mutations in TRAIP, encoding an E3 RING ubiquitin 
ligase, in patients with microcephalic primordial dwarfism/Seckel syndrome. We establish that TRAIP 
relocalizes to sites of DNA damage where it is required for optimal phosphorylation of H2AX and 
RPA2 during S-phase in response to UV irradiation, as well as fork progression through UV-induced 
DNA lesions. TRAIP is necessary for efficient cell cycle progression and mutations in TRAIP therefore 
limit cellular proliferation, providing a potential mechanism for microcephaly and dwarfism 
phenotypes. Human genetics thus identifies TRAIP as a novel component of the DNA damage 
response to replication-blocking DNA lesions. 
 
  
INTRODUCTION 
The rapid cellular response to genomic insults is facilitated by signaling cascades which utilize 
diverse post-translational modifications, particularly ubiquitylation and phosphorylation1,2. 
Mutations in genes encoding many components of DNA damage response (DDR) signaling pathways 
have been identified in human disease1, reflecting the central importance of DNA repair in 
maintaining cellular homeostasis. Mutations in DDR genes have been associated with increased 
cancer predisposition, immunodeficiency, premature ageing and neurodegeneration3,4. Growth 
restriction and microcephaly are also features of certain DNA repair disorders5-9. Microcephalic 
primordial dwarfism (MPD) represents a group of single gene disorders10 typically inherited as 
autosomal recessive traits, that includes Seckel syndrome11,12, Microcephalic Osteodysplastic 
Primordial Dwarfism (MOPD) syndromes13,14 and Meier-Gorlin syndrome15,16. In MPD, growth is 
restricted prenatally and remains severely restricted postnatally, resulting in an adult height as short 
as 1 meter17. Marked reduction in brain size, manifesting as microcephaly, distinguishes MPD from 
other forms of dwarfism, and mutations in genes encoding components of key cellular processes, 
including centrosome biogenesis, mitotic spindle function, replication licensing and DNA damage 
repair, have been identified in these disorders10. Particularly, multiple components of ATR-
dependent DDR signaling have been implicated in Seckel syndrome and MOPD II, including 
mutations in ATR, ATRIP, RBBP8 (encoding CtIP) and PCNT7,8,18,19. 
To identify further primordial dwarfism genes relevant to cell cycle and DNA repair processes, we 
performed whole-exome sequencing (WES) on a group of primordial dwarfism patients. Here, we 
report the identification of TRAIP as a novel human disease-associated gene, and implicate the 
protein it encodes in regulating the DNA damage response to genotoxic lesions during replication. 
 
RESULTS 
TRAIP is a novel gene mutated in primordial dwarfism 
We performed WES to establish a molecular diagnosis for a child with severe microcephalic 
primordial dwarfism. After filtering to remove common variants (minor allele frequency (MAF) > 
0.005), analysis under a recessive inheritance model identified a homozygous nonsense mutation in 
TRAIP, c.553C>T, resulting in a premature stop codon, p.Arg185* (Fig. 1a). Sanger sequencing 
confirmed the presence of this mutation and its appropriate segregation in the family, with both 
parents being heterozygous carriers. The variant was not detected on sequencing of 380 control 
chromosomes, nor was it present in 1000 Genomes, EVS or EXaC public variant databases, in keeping 
with it being a rare recessive pathogenic mutation. Sanger resequencing of the coding exons and 
splice junctions of TRAIP in 262 primary microcephaly and primordial dwarfism patients identified a 
second patient, homozygous for the same mutation, p.Arg185*. Notably the two patients were born 
to non-consanguineous parents and originated from different countries with the families having no 
known relationship. However, high density genome-wide SNP genotyping demonstrated regions of 
homozygosity surrounding TRAIP in both patients of 4.6 and 8.4Mb respectively, consistent with 
unrecognized parental relatedness in each family (Supplementary Fig. 1a). As well, analysis of 
genome-wide SNP genotype data using FEstim20  provided an inbreeding coefficient estimate of 
0.003 for P2, equivalent to the inbreeding coefficient of 3rd cousin parents and also consistent with 
unknown parental consanguinity in this family (Supplementary Fig. 1b). Furthermore a 4.3 Mb 
homozygous haplotype was shared between P1 and P2 for the region immediately surrounding 
TRAIP, signifying a distant familial link with shared ancestry many generations previously despite 
their geographical separation (Supplementary Fig. 1a). 
Additional WES on a cohort of patients with a presumptive diagnosis of Seckel syndrome (n=28), 
identified a further consanguineous family with a different mutation in TRAIP. In this family, a 
homozygous missense mutation was identified, c.52C>T, resulting in an arginine to cysteine 
substitution at codon 18 (p.Arg18Cys) (Fig. 1a). This highly conserved residue (Fig. 1b) lies within a 
RING domain, with the mutation resulting in a large physiochemical change, predicted 
bioinformatically to be deleterious (Alamut, Interactive Biosoftware Inc). The addition of a further 
cysteine residue is thought likely to be structurally deleterious, given that RING domains are defined 
by a specific motif of cysteine and histidine residues that bind zinc divalent cations to establish their 
tertiary structure21. 
The clinical phenotype of all three patients was remarkably similar (Fig. 1, Table 1, Supplementary 
Note). They shared almost identical growth parameters, with global growth failure of prenatal onset 
and extreme disproportionate microcephaly (Fig. 1c, Table 1). Neuroimaging demonstrated reduced 
cerebral cortical size with simplified gyral folding (Fig. 1d). Craniofacial similarities included a narrow 
elongated face and micrognathia (Fig. 1e). Additionally, significant morbidity from infections was 
evident. Patient 1 (P1) and Patient 2 (P2) had frequent lower respiratory tract infections, with P1 
dying of respiratory failure aged 10 years as a result of chronic lung disease. Furthermore, P1 had 
two siblings who died in early infancy22. However, aside from P2 who had a persistent lymphopenia, 
there was no evidence of adaptive immune deficits on clinical investigation.  
On the basis of the mutations identified and phenotypic similarities between patients, we concluded 
that TRAIP was a novel gene associated with primordial dwarfism. TRAIP (TNF receptor associated 
factor (TRAF)-interacting partner; TRIP; RNF206) is a RING domain-type E3 ubiquitin ligase23 
originally identified as a negative regulator of innate immune signaling24. As it ubiquitylates TBK125, a 
key transducer of Toll-receptors and RIG-I, this could explain the recurrent respiratory illnesses in 
the patients; however the mechanistic basis for the primordial dwarfism phenotype was less 
evident. Therefore we proceeded to investigate the functional basis for the growth-related 
phenotypes. 
 
TRAIP protein levels are markedly depleted in patient cells 
We obtained cell lines from all three patients and characterized these to confirm the deleterious 
effect of mutations on the TRAIP protein. The Arg185* mutation introduces a premature stop codon 
in exon 7 and would be expected to cause nonsense-mediated decay of the TRAIP transcript. RT-PCR 
was therefore performed on RNA extracted from patient cells to assess transcript levels. This 
demonstrated marked reduction in TRAIP mRNA both in the immortalized lymphoblastoid cell line 
from P1 and a primary fibroblast cell line from P2 (Fig. 2a). Notably, low levels of residual full-length 
mRNA as well as alternatively spliced transcripts were evident. Cloning and sequencing of these RT-
PCR products demonstrated that the latter included transcripts that are predicted to produce in-
frame deletions of the TRAIP protein of 37 or 99 amino acids (Fig. 2a).  
Immunoblotting was next performed to establish the consequence of the mutation at the protein 
level. TRAIP protein levels were greatly reduced in both patient cell lines P1 and P2 carrying the 
Arg185* mutation (Fig. 2b).  A TRAIP protein of comparable size (47 kDa) to wild-type TRAIP (53 kDa) 
was only detectable on prolonged immunoblot exposure (Supplementary Fig. 2) while a truncated 
protein isoform of 184 amino acids was not observed, despite the polyclonal antibody (raised against 
residues 1-270) being able to efficiently detect both in vitro synthesized truncated and full-length 
proteins (Supplementary Fig. 3). In conjunction with RT-PCR findings, detection of residual TRAIP 
protein expression suggests that the mutation is a severe hypomorph, likely compromising, but not 
completely abrogating TRAIP cellular function. Consistent with this, a knockout mouse model 
established that Traip is essential for early embryonic development, with embryonic lethality seen at 
gastrulation and a reduction in cell number and embryo growth occurring as early as E5.526. 
The Arg18Cys mutation had no effect on transcript levels (Supplementary Fig. 4), but also resulted in 
marked reduction of TRAIP protein levels in primary fibroblasts derived from patient P3 (Fig. 2b), 
probably reflecting reduced protein stability resulting from the missense mutation.  We therefore 
concluded that patient TRAIP mutations would likely lead to substantial impairment of its cellular E3 
ligase activity through depletion of overall protein levels.  
 
TRAIP localizes to sites of UV-induced DNA damage 
Phenotypically, TRAIP patients were reminiscent of individuals with Seckel syndrome that have 
defects in ATR pathway signaling7,8, particularly with their disproportionately reduced head size. We 
therefore postulated that TRAIP could be a DDR protein acting in this pathway. Consistent with this, 
live-imaging of GFP-TRAIP protein demonstrated rapid re-localization from a pan-nuclear distribution 
to sites of DNA damage after UV laser microirradiation, irrespective of addition of BrdU as a DNA 
damage sensitizer (Fig. 3a). Colocalization was observed both with H2AX and RFP-PCNA (Fig. 3b). 
Proximity ligation assays (PLA) detected GFP-TRAIP in close proximity (<40 nm) to PCNA in 
undamaged cells, suggesting it can be present at replication foci in undamaged cells.  This 
association was substantially enriched after UV-C irradiation (Fig. 3c, d, p< 0.001), consistent with 
TRAIP localizing with PCNA at sites of DNA damage. Relocalisation of TRAIP to sites of UV-induced 
DNA damage was confirmed using localized UV-C irradiation through 3 μm isopore membrane filters, 
after which GFP-TRAIP was detected in irradiated regions, along with multiple DNA damage repair 
markers, including H2AX and RPA2 (Fig. 3e). Notably, TRAIP was a highly significant hit in a recently 
reported high-throughput mass spectroscopy screen for proteins recruited to replication blocking 
DNA lesions27. As well as re-localizing to DNA damage sites, we also noted that TRAIP protein levels 
were regulated by DNA damage, with proteasome-mediated degradation observed at later time 
points after UV treatment (Supplementary Fig. 5), similar to certain DDR proteins involved in repair 
of UV lesions28.  
 
TRAIP is required for RPA2 and H2AX phosphorylation in S-phase   
To assess whether TRAIP was a novel component of ATR-dependent DDR signaling, siRNA-depleted 
HeLa cells were irradiated with 10 J/m2 UV and a time course was performed to monitor activation 
of this signaling pathway. Unlike ATR/ATRIP deficient cells7,8, ATR-mediated phosphorylation of the 
downstream kinase CHK1 was not impaired by TRAIP depletion (Fig. 4a). Additionally, 
phosphorylation of the ATR substrates NBS1, SMC1 and Ser33-RPA2, as well as the activation of ATM 
and DNA-PK were also unaffected by TRAIP knockdown (Fig. 4a, Supplementary Fig. 6a, b). 
However, a striking reduction in phosphorylation of Ser4/Ser8-RPA2 and H2AX was seen in HeLa cells 
after TRAIP siRNA and in patient fibroblasts (Fig. 4b-e). Complementation of TERT-immortalized P2 
fibroblasts (P2TERT) by retroviral transduction of wild-type TRAIP (P2TERT+TRAIP) restored RPA2/H2AX 
phosphorylation to normal levels after UV-C irradiation in P2TERT+TRAIP cells, confirming that these 
phosphorylation defects were directly due to loss of TRAIP (Fig. 4f, Supplementary Fig. 6c). Overall, 
phosphorylation of other ATR, ATM and DNA-PK substrates was comparable between P2TERT and 
P2TERT+TRAIP cells (Supplementary Fig. 6d). Given this and the normal level of DNA damage-induced 
phosphorylation of multiple downstream substrates of ATR in siTRAIP-depleted cells, along with a 
normal G2/M checkpoint in response to UV irradiation (Supplementary Fig. 6e), we concluded that 
TRAIP deficiency did not give rise to a general defect in ATR signaling, but rather compromised 
phosphorylation of RPA and H2AX following the induction of UV damage. 
Since DNA damage response to UV lesions occurs throughout the cell cycle, we next investigated 
when TRAIP is required to promote RPA2 and H2AX phosphorylation. Using quantitative 
immunofluorescence, we found that Ser4/Ser8-RPA2 and H2AX phosphorylation induced by UV-C 
exposure was significantly reduced in EdU-labeled TRAIP patient P2TERT cells but not in EdU-negative 
cells, indicating that TRAIP is specifically required during S-phase for optimal DNA damage-
dependent phosphorylation of these proteins (Fig. 4g, Supplementary Fig. 7). Given that pSer4/Ser8-
RPA2 has been associated with the resection of DNA double strand breaks (DSBs), a process that 
may occur when replication forks encounter UV lesions during S-phase, we considered whether 
differences in DSBs in patient cells could account for the altered RPA2/H2AX phosphorylation. To 
assess this, we performed neutral comet assays, which demonstrated equal levels of DSBs in TRAIP 
patient and control primary fibroblast cell lines after UV-irradiation (Supplementary Fig. 8). This 
indicated that reduced RPA2/H2AX phosphorylation was not a consequence of altered frequency of 
DSB formation. We therefore concluded that TRAIP is required for optimal H2AX and RPA2 
phosphorylation in response to UV-induced damage encountered in S-phase. 
 
Loss of TRAIP impairs cellular proliferation  
We next considered how TRAIP mutations might reduce organism growth. Many primordial 
dwarfism genes are thought to cause reduced size through lowering the efficiency of cellular 
proliferation10. As TRAIP is required for efficient cell proliferation both in human primary cells and 
during mammalian development26,29, we assessed the consequences of these mutations on growth 
rates of primary patient cell lines. We found that doubling times of patient fibroblasts (P2 and P3) 
were significantly slower than passage-matched control fibroblasts (Fig. 5a, c). Furthermore, this 
growth defect was complemented by retroviral transduction of patient cells with wild-type TRAIP 
(Fig. 5b), demonstrating that impaired proliferation was a direct consequence of TRAIP loss in 
patient cells, and indicating that prolonged cell cycle likely underlies the patient dwarfism 
phenotype.  
To further characterize these cell cycle effects, we performed BrdU-pulse chase flow cytometry time 
courses using isogenic systems. Both TRAIP-depleted HeLa cells (Fig. 5d) and P2TERT patient cells 
(Supplementary Fig. 9b, c) retained higher 4n DNA content at later time points than matched 
controls (p = 0.0012, p=0.0135, respectively). This could not be accounted for by an increased 
percentage of mitotic cells (Supplementary Fig. 9a), and therefore represented an increase in late S-
phase and/or G2 cells consistent with a replicative origin for the cell cycle delay. 
To gain a further understanding of TRAIP’s role during replication, we then examined replication fork 
dynamics in patient cells by DNA fiber analysis in patient cells. Replication fork velocity, inter-origin 
distance and fork stalling (1st label termination events) were not significantly altered in untreated 
TRAIP patient cells (Supplementary Fig. 10), suggesting that TRAIP deficiency does not result in 
significant global DNA replication defects. Given that TRAIP is required for efficient progression 
through S-phase and S-phase-specific alterations in RPA2/H2AX phosphorylation after DNA damage 
induction, we postulated that TRAIP is instead required when the replication fork encounters 
genotoxic lesions. Consistent with this, following UV irradiation TRAIP patient cells exhibited 
significantly increased levels of fork stalling (Fig. 6a), and consequently substantially reduced levels 
of ongoing replicating forks. Moreover, while overall fork velocities were slowed in TRAIP patient 
cells after UV-C irradiation at rates comparable to control cells (Supplementary Fig. 11a), substantial 
fork asymmetry in TRAIP-deficient cells was observed (Fig. 6b, c), indicative of a problem with fork 
progression past bulky UV adducts. Importantly, P2TERT+TRAIP complemented cells exhibited normal 
levels of fork stalling (Supplementary Fig. 11b) and fork symmetry following UV-C irradiation 
(Supplementary Fig. 11c), establishing that TRAIP was specifically required to prevent fork stalling at 
UV lesions. Notably, levels of new origin firing were not increased in UV-C treated patient fibroblasts 
(Fig. 6a), indicating that the ATR-dependent intra-S-phase checkpoint remained intact. In contrast to 
UV, replication stress induced by low dose aphidicolin, or treatment with a cross-link inducing agent, 
mitomycin C (MMC), did not result in increased fork asymmetry in TRAIP patient cells compared with 
control cells (Supplementary Fig. 11c-e). Likewise, MMC treatment did not cause increased fork 
stalling in TRAIP-deficient cells (Supplementary Fig. 11c, d). Normal levels of fork recovery were also 
seen following replication fork stalling after hydroxyurea (HU) treatment (Supplementary Fig. 12), 
establishing that fork stability and replication restart are not generally impaired in TRAIP-deficient 
cells. Therefore, rather than a general requirement to promote genome replication under conditions 
of replication stress, TRAIP appears to have a role ensuring fork progression past bulky polymerase-
stalling DNA lesions such as UV-photo-products.  
 
DISCUSSION 
Here, we report the identification of TRAIP as a human disease-associated gene and implicate it in 
DNA damage response to genotoxic lesions during genome replication. DNA damage encountered 
during S-phase is especially problematic, with substantial risks of mutation and/or genomic 
rearrangements arising from replication intermediates. Hence, multiple cellular mechanisms are 
employed to ensure replication fork stability and appropriate repair of DNA lesions30. Given our data 
demonstrating increased fork stalling and asymmetry following exposure to UV, but not HU, 
aphidicolin or MMC, TRAIP is likely to promote repair or bypass of replication blocking lesions 
induced by UV, rather than playing a general role in stabilizing or promoting restart of stalled 
replication forks.  
A role for TRAIP in promoting translesion synthesis (TLS) has been raised by a developmental study 
of the Drosophila ortholog nopo which reported polyubiquitylation of DNA polymerase η (Pol η) 31. 
However, the functional relevance of this observation is unclear since experiments were carried out 
in the absence of UV-induced damage. As well, Pol η undergoes active deubiquitylation in 
mammalian cells after UV irradiation to promote its recruitment to repair sites32. The patient 
phenotype is also inconsistent with a role for TRAIP in TLS, as it is distinct from Xeroderma-
Pigmentosum-variant (XP-V)33 that results from Pol η mutations34,35. XP-V manifests as freckling, 
increased sun sensitivity and skin cancer, rather than prenatal onset growth failure and 
microcephaly. TRAIP patients lack such dermatological features and cancer predisposition has not 
been observed, although all are still children. Furthermore, TRAIP cells do not exhibit the increased 
ATR pathway activation seen in XP-V cells36. Hence, TRAIP more likely acts in a parallel, TLS-
independent process, to overcome UV-C replication blocking lesions. TRAIP could instead be 
involved in a homologous recombination dependent mechanism to resolve such replication blocks, 
particularly given the role of RPA hyperphosphorylation in recruiting Rad51 after replication fork 
arrest37. Decreased RPA2 (and H2AX) phosphorylation might directly account for impaired fork 
progression at such UV-induced lesions, although how TRAIP promotes H2AX and RPA 
phosphorylation remains to be defined. TRAIP could act either by positively regulating a DDR protein 
kinase at UV-induced damage sites, or suppressing PP2A or PP4 protein phosphatases that 
dephosphorylate γH2AX and pSer4/Ser8-RPA238-41.  
Ubiquitylation regulates many key DNA damage response processes2, with several DDR-associated 
E3 ubiquitin ligases, including BRCA142,43, RNF16844 and FANCL45 implicated in human disease. The 
identification of additional TRAIP ubiquitylation substrates will be important to understand the 
disease process, and will likely provide further insights into its role at replication blocking lesions. It 
also remains to be formally established if its DNA repair/replication roles are dependent on a 
functional RING domain, as TRAIP could have E3 ligase-independent functions.   
Total cell number is the predominant determinant of size in mammals46. Similarly, reduced cellularity 
from early development is believed to cause primordial dwarfism10, with decrease in neuronal 
number generated during neurogenesis underlying the microcephaly. The DNA replication 
machinery is implicated in other forms of microcephalic dwarfism47-49 and replication stress during 
embryonic development underlies Seckel syndrome due to ATR mutations50. Therefore, perturbed 
cell cycle progression as a consequence of replication blocking lesions could account for the 
microcephaly and dwarfism present in our TRAIP patients. For the cellular studies described here, 
UV-C irradiation was used to generate replication-blocking lesions. Most commonly these will be 
bulky cyclobutane pyrimidine dimers, which are unlikely to be encountered in the embryo. However 
during development, different replication blocking DNA lesions are present, with potential 
candidates being those arising from oxidative damage51 or aldehydes52. Therefore endogenous DNA 
lesions may pose difficulties for TRAIP-deficient cells during development, and result in depleted 
overall cell numbers (Model, Supplementary Fig. 13) that underlies other microcephalic dwarfism 
disorders 48,50,53.  
In summary, we identify TRAIP as a novel disease-associated gene, and through investigating the 
cellular basis of the human phenotype establish its involvement in DDR. TRAIP promotes H2AX and 
RPA2 phosphorylation following replication-associated DNA damage, and assists fork progression at 
UV-induced replication blocking lesions. Developmentally viable alleles identified through human 
genetics will facilitate future studies investigating its roles during embryogenesis, while identification 
of TRAIP substrates and mechanistic studies of its role in response to DNA lesions encountered 
during DNA synthesis, will provide further insight into the key cellular processes maintaining genome 
stability during replication.   
ACCESSION CODES and URLs 
Exome sequence data has been deposited at the European Genome-phenome Archive (EGA), which 
is hosted by the EBI (https://www.ebi.ac.uk/ega/), under accession number EGAS00001001501. 
ACKNOWLEDGMENTS 
We thank the families and clinicians for their involvement and participation; N. Hastie, W. Bickmore, 
D. Fitzpatrick, J.-C. Acosta, M. Nowotny, V.Vitart and A. Lehmann for helpful discussions; R. Geahlen 
(Purdue University, USA), S. Taylor (University of Manchester), D.-J. Kleinjan (University of 
Edinburgh), A. Lichawska and J. Mansfeld (Gurdon Institute) for their kind gifts of reagents; J. Ding, P. 
Hari and E. Milz for technical assistance; E. Freyer for assistance with FACS analysis; the IGMM core 
sequencing service; A. Wheeler and the IGMM imaging facility for assistance with microscopy, 
E.Maher and A.Pearce for performing SNP genotyping arrays. This work was supported by funding 
from the Medical Research Council and the European Research Council (ERC, 281847) (A.P.J.), the 
Lister Institute for Preventative Medicine (A.P.J. and G.S.S.), Medical Research Scotland (L.S.B.), 
German Federal Ministry of Education and Research (BMBF, 01GM1404) and E-RARE network 
EuroMicro (B.W), Wellcome Trust (M. Hurles), CMMC (P.N.), Cancer Research UK (C17183/A13030) 
(G.S.S. and M.R.H), Swiss National Science Foundation (P2ZHP3_158709) (O.M.), AIRC (12710) and 
ERC/EU FP7 (CIG_303806) (S.S.), Cancer Research UK (C6/A11224) and ERC/EU FP7 (HEALTH-F2-
2010-259893) (A.N.B. and S.P.J.). 
AUTHOR CONTRIBUTIONS 
M.E. Hurles, L.S.B., M. Halachev, G.Y., J.A., H.T., P.N., and B.W. performed exome sequencing and 
analysis. L.S.B., M.E. Harley, G.Y., S.M., and B.W. performed sequencing, genotyping, linkage analysis 
and other molecular genetics experiments. M.E. Harley, O.M., A.L., M.R.H., A.N.B., A.Z., K.R., 
M.A.M.R., A.F., C.-A.M., S.S., S.P.J. and G.S.S. designed and performed the cell biology experiments. 
N.H.E., L.G., L.C., M.M., M.S., M.B.B., K.J.M., and B.W. ascertained subjects, obtained samples and/or 
assisted with clinical studies. M.E. Harley and A.P.J. wrote the manuscript. The study was planned 
and supervised by B.W., G.S.S. and A.P.J.  
COMPETING FINANCIAL INTERESTS 
M.E. Hurles is a co-founder, share-holder and consultant to Congenica Ltd, a clinical diagnostics 
company.  
REFERENCES 
1. Ciccia, A. & Elledge, S.J. The DNA damage response: making it safe to play with knives. Mol 
Cell 40, 179-204 (2010). 
2. Jackson, S.P. & Durocher, D. Regulation of DNA damage responses by ubiquitin and SUMO. 
Mol Cell 49, 795-807 (2013). 
3. Slatter, M.A. & Gennery, A.R. Primary immunodeficiencies associated with DNA-repair 
disorders. Expert Rev Mol Med 12, e9 (2010). 
4. Woods, C.G. DNA repair disorders. Arch Dis Child 78, 178-184 (1998). 
5. German, J. Bloom's syndrome. I. Genetical and clinical observations in the first twenty-seven 
patients. Am J Hum Genet 21, 196-227 (1969). 
6. Murray, J.E. et al. Extreme growth failure is a common presentation of ligase IV deficiency. 
Hum Mutat 35, 76-85 (2014). 
7. O'Driscoll, M., Ruiz-Perez, V.L., Woods, C.G., Jeggo, P.A. & Goodship, J.A. A splicing mutation 
affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel 
syndrome. Nat Genet 33, 497-501 (2003). 
8. Ogi, T. et al. Identification of the first ATRIP-deficient patient and novel mutations in ATR 
define a clinical spectrum for ATR-ATRIP Seckel Syndrome. PLoS Genet 8, e1002945 (2012). 
9. Jackson, S.P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 
461, 1071-1078 (2009). 
10. Klingseisen, A. & Jackson, A.P. Mechanisms and pathways of growth failure in primordial 
dwarfism. Genes Dev 25, 2011-2024 (2011). 
11. Majewski, F. & Goecke, T. Studies of microcephalic primordial dwarfism I: approach to a 
delineation of the Seckel syndrome. Am J Med Genet 12, 7-21 (1982). 
12. Seckel, H.P.G. Bird-Headed Dwarfs, (S.Karger, Basel, 1960). 
13. Majewski, F., Ranke, M. & Schinzel, A. Studies of microcephalic primordial dwarfism II: the 
osteodysplastic type II of primordial dwarfism. Am J Med Genet 12, 23-35 (1982). 
14. Majewski, F., Stoeckenius, M. & Kemperdick, H. Studies of microcephalic primordial 
dwarfism III: an intrauterine dwarf with platyspondyly and anomalies of pelvis and clavicles--
osteodysplastic primordial dwarfism type III. Am J Med Genet 12, 37-42 (1982). 
15. Bongers, E.M. et al. Meier-Gorlin syndrome: report of eight additional cases and review. Am 
J Med Genet 102, 115-124 (2001). 
16. Gorlin, R.J., Cervenka, J., Moller, K., Horrobin, M. & Witkop, C.J., Jr. Malformation 
syndromes. A selected miscellany. Birth Defects Orig Artic Ser 11, 39-50 (1975). 
17. Rauch, A. et al. Mutations in the Pericentrin (PCNT) Gene Cause Primordial Dwarfism. 
Science 319, 816-819 (2008). 
18. Griffith, E. et al. Mutations in pericentrin cause Seckel syndrome with defective ATR-
dependent DNA damage signaling. Nat Genet 40, 232-236 (2008). 
19. Qvist, P. et al. CtIP Mutations Cause Seckel and Jawad Syndromes. PLoS Genet 7, e1002310 
(2011). 
20. Leutenegger, A.L. et al. Using genomic inbreeding coefficient estimates for homozygosity 
mapping of rare recessive traits: application to Taybi-Linder syndrome. Am J Hum Genet 79, 
62-66 (2006). 
21. Borden, K.L. & Freemont, P.S. The RING finger domain: a recent example of a sequence-
structure family. Curr Opin Struct Biol 6, 395-401 (1996). 
22. Silengo, M., Del Monaco, A., Linari, A. & Lala, R. Low birth-weight, microcephalic 
malformation syndrome in a 46,XX girl and her 46,XY sister with agonadism: third report of 
the Kennerknecht syndrome or autosomal recessive Seckel-like syndrome with previously 
undescribed genital anomalies. Am J Med Genet 101, 275-278 (2001). 
23. Besse, A., Campos, A.D., Webster, W.K. & Darnay, B.G. TRAF-interacting protein (TRIP) is a 
RING-dependent ubiquitin ligase. Biochem Biophys Res Commun 359, 660-664 (2007). 
24. Lee, S.Y., Lee, S.Y. & Choi, Y. TRAF-interacting protein (TRIP): a novel component of the 
tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits 
TRAF2-mediated NF-kappaB activation. J Exp Med 185, 1275-1285 (1997). 
25. Zhang, M. et al. TRAF-interacting protein (TRIP) negatively regulates IFN-beta production and 
antiviral response by promoting proteasomal degradation of TANK-binding kinase 1. J Exp 
Med 209, 1703-1711 (2012). 
26. Park, E.S. et al. Early embryonic lethality caused by targeted disruption of the TRAF-
interacting protein (TRIP) gene. Biochem Biophys Res Commun 363, 971-977 (2007). 
27. Raschle, M. et al. DNA repair. Proteomics reveals dynamic assembly of repair complexes 
during bypass of DNA cross-links. Science 348, 1253671 (2015). 
28. Han, C. et al. Cdt2-mediated XPG degradation promotes gap-filling DNA synthesis in 
nucleotide excision repair. Cell Cycle 14, 1103-1115 (2015). 
29. Almeida, S., Ryser, S., Obarzanek-Fojt, M., Hohl, D. & Huber, M. The TRAF-interacting protein 
(TRIP) is a regulator of keratinocyte proliferation. J Invest Dermatol 131, 349-357 (2011). 
30. Branzei, D. & Foiani, M. Maintaining genome stability at the replication fork. Nat Rev Mol 
Cell Biol 11, 208-219 (2010). 
31. Wallace, H.A. et al. TRIP/NOPO E3 ubiquitin ligase promotes ubiquitylation of DNA 
polymerase eta. Development 141, 1332-1341 (2014). 
32. Bienko, M. et al. Regulation of translesion synthesis DNA polymerase eta by 
monoubiquitination. Mol Cell 37, 396-407 (2010). 
33. Lehmann, A.R., McGibbon, D. & Stefanini, M. Xeroderma pigmentosum. Orphanet J Rare Dis 
6, 70 (2011). 
34. Masutani, C. et al. The XPV (xeroderma pigmentosum variant) gene encodes human DNA 
polymerase eta. Nature 399, 700-704 (1999). 
35. Johnson, R.E., Kondratick, C.M., Prakash, S. & Prakash, L. hRAD30 mutations in the variant 
form of xeroderma pigmentosum. Science 285, 263-265 (1999). 
36. Despras, E., Daboussi, F., Hyrien, O., Marheineke, K. & Kannouche, P.L. ATR/Chk1 pathway is 
essential for resumption of DNA synthesis and cell survival in UV-irradiated XP variant cells. 
Hum Mol Genet 19, 1690-1701 (2010). 
37. Shi, W. et al. The role of RPA2 phosphorylation in homologous recombination in response to 
replication arrest. Carcinogenesis 31, 994-1002 (2010). 
38. Nakada, S., Chen, G.I., Gingras, A.C. & Durocher, D. PP4 is a gamma H2AX phosphatase 
required for recovery from the DNA damage checkpoint. EMBO Rep 9, 1019-1026 (2008). 
39. Chowdhury, D. et al. A PP4-phosphatase complex dephosphorylates gamma-H2AX generated 
during DNA replication. Mol Cell 31, 33-46 (2008). 
40. Chowdhury, D. et al. gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates 
DNA double-strand break repair. Mol Cell 20, 801-809 (2005). 
41. Feng, J. et al. Protein phosphatase 2A-dependent dephosphorylation of replication protein A 
is required for the repair of DNA breaks induced by replication stress. Mol Cell Biol 29, 5696-
5709 (2009). 
42. Taylor, S.S. & McKeon, F. Kinetochore localization of murine Bub1 is required for normal 
mitotic timing and checkpoint response to spindle damage. Cell 89, 727-735 (1997). 
43. Soria, G., Polo, S.E. & Almouzni, G. Prime, repair, restore: the active role of chromatin in the 
DNA damage response. Mol Cell 46, 722-734 (2012). 
44. Lancaster, M.A. & Knoblich, J.A. Spindle orientation in mammalian cerebral cortical 
development. Curr Opin Neurobiol 22, 737-746 (2012). 
45. Lessel, D. et al. Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic 
instability and progeroid features. Nat Genet 46, 1239-1244 (2014). 
46. Conlon, I. & Raff, M. Size control in animal development. Cell 96, 235-244 (1999). 
47. Bicknell, L.S. et al. Mutations in the pre-replication complex cause Meier-Gorlin syndrome. 
Nat Genet 43, 356-359 (2011). 
48. Bicknell, L.S. et al. Mutations in ORC1, encoding the largest subunit of the origin recognition 
complex, cause microcephalic primordial dwarfism resembling Meier-Gorlin syndrome. Nat 
Genet 43, 350-355 (2011). 
49. Guernsey, D.L. et al. Mutations in origin recognition complex gene ORC4 cause Meier-Gorlin 
syndrome. Nat Genet 43, 360-364 (2011). 
50. Murga, M. et al. A mouse model of ATR-Seckel shows embryonic replicative stress and 
accelerated aging. Nat Genet 41, 891-898 (2009). 
51. Cooke, M.S., Evans, M.D., Dizdaroglu, M. & Lunec, J. Oxidative DNA damage: mechanisms, 
mutation, and disease. FASEB J 17, 1195-1214 (2003). 
52. Langevin, F., Crossan, G.P., Rosado, I.V., Arends, M.J. & Patel, K.J. Fancd2 counteracts the 
toxic effects of naturally produced aldehydes in mice. Nature 475, 53-58 (2011). 
53. Frank, K.M. et al. DNA ligase IV deficiency in mice leads to defective neurogenesis and 
embryonic lethality via the p53 pathway. Mol Cell 5, 993-1002 (2000). 
 
  
FIGURE LEGENDS 
 
 
Figure 1. Mutations in TRAIP cause primordial dwarfism 
(a) Mutations identified in TRAIP. Top, schematic of TRAIP gene structure; middle, TRAIP protein 
structure; bottom, sequence electropherograms demonstrating (middle, right panels) homozygous 
nonsense mutations in Patient 1 (P1) and Patient 2 (P2) and (left) a homozygous missense mutation, 
Arg18Cys in Patient 3 (P3). (b) A physiochemically similar residue is present at codon 18 in all 
vertebrates. Sequence alignments of Homo sapiens, Pan troglodytes, Mus musculus, Gallus gallus, 
Xenopus tropicalis and Danio rerio using Clustal W. (c) Patients with TRAIP mutations have prenatal 
onset severe growth failure with disproportionate microcephaly. Birth weight (BWGT), current 
height (HGT) and current head circumference (OFC) plotted as z-scores (standard deviations from 
population mean for age and sex). 97.5% of general population will lie above the dashed line at –2 
S.D. Black bars indicate mean values. (d) Cerebral cortical size is markedly reduced with 
simplification of gyral folding. MRI T2-weighted sagittal and axial images of P3 (age 3 years) 
compared with control scans of a healthy child (age 3 years 1 month). Scale bar, 2 cm. (e) 
Photographs of affected individuals with TRAIP mutations demonstrating facial similarities, including 
an elongated narrow face and micrognathia. Informed consent to publish photographs was obtained 
from families. 
 
Figure 2. TRAIP mutations result in reduced cellular levels of TRAIP protein 
(a) The Arg185* mutation severely reduces TRAIP transcript levels in P1 and P2 patient cell lines. RT-
PCR using primers in 5’ and 3’ UTR to amplify TRAIP transcripts in primary fibroblasts and 
lymphoblastoid cell lines (LCLs) demonstrates marked decrease in full length TRAIP transcript, 
consistent with nonsense-mediated decay. Additional low intensity PCR products are evident, that 
represent alternatively spliced transcripts, confirmed by subcloning and Sanger sequencing (lower 
panels). These include transcripts, which through omission of exon 7, or exons 6, 7 and 8, retain an 
open reading frame and result in protein products with small internal deletions. Loading control, 
GAPDH. (b) TRAIP protein levels are reduced in patients with Arg185* and the Arg18Cys mutations. 
Immunoblotting with an affinity purified rabbit anti-TRAIP antibody raised against recombinant 
TRAIP protein demonstrates reduced levels of the 53 kDa TRAIP protein in P3, and marked depletion 
in P1 and P2 where protein is only detectable on prolonged exposure (Supplementary Fig. 2). 
Loading controls, actin and vinculin.  
 
 
Figure 3. TRAIP localizes to sites of UV-induced DNA damage 
(a) TRAIP localizes to DNA damage sites induced by UV laser microirradiation both in the absence 
and presence of pre-treatment with BrdU as a damage sensitizer. Representative images, before and 
after UV laser microirradiation. Scale bar, 5 µm. (b) GFP-TRAIP colocalizes with γH2AX and with RFP-
PCNA at sites of UV laser-induced damage. Representative images of UV laser-irradiated GFP-TRAIP 
expressing cells immunostained for γH2AX (pre-sensitized with BrdU) or co-expressing RFP-PCNA (no 
BrdU pre-treatment) as indicated. Scale bar, 5 µm. (c, d) GFP-TRAIP is detected by a Proximity 
Ligation Assay (PLA) in close proximity to PCNA, an association enhanced after UV-induced damage. 
(c) Representative images of PLA signals/nucleus in doxycycline-inducible GFP-TRAIP HeLa cells 
before and after damage with 25 J/m2 UV-C. Scale bar, 5 µm. (d) Quantification of PLA 
signals/nucleus. Box plots, center line denote mean values, box 25/75 %, whiskers 5/95 %, data 
pooled from n=2 independent experiments, n>65 data points per condition per experiment; Mann 
Whitney rank sum test: *** p<0.001. (e) TRAIP accumulates at sites of localized UV damage, 
colocalising with RPA and γH2AX.  Representative immunofluorescence images of MRC5 cells 
transfected with GFP-TRAIP or GFP alone after UV-C irradiation through 3 μm microfilters. Scale bar, 
5 µm.  
 
Figure 4. TRAIP is required for UV-induced RPA2 and H2AX phosphorylation during S-phase 
(a) Phosphorylation of downstream ATR substrates is unaffected by TRAIP depletion. HeLa cells were 
transfected with RNAi against TRAIP or luciferase (control). After 72h, cells were UV-C treated, 
before harvesting at indicated times. Cell lysates were analyzed by Western blot as indicated. (b, c) 
TRAIP loss reduces RPA2 phosphorylation and histone H2AX phosphorylation (γH2AX) in response to 
UV. HeLa cells transfected with TRAIP and control siRNAs (b) or primary patient fibroblasts (c) were 
UV-C treated, harvested and immunoblotted as indicated. (d, e) Quantification of pS4/S8-RPA2 (d) 
and γH2AX (e) in primary fibroblasts after UV. Chemiluminescence from Western blots quantified 
using ImageQuant. Mean ± SEM, n=3 experiments; values normalized to total RPA2 signal; two-way 
ANOVA across all time points: *** p<0.001, ** p<0.01. (f) Retroviral complementation with wild-type 
TRAIP rescues impaired phosphorylation of RPA2 and H2AX after UV-C irradiation in TRAIPArg185* 
cells. Fibroblasts derived from P2Arg185* were immortalized with hTERT, denoted P2TERT; and 
reconstituted with pMSCV-TRAIP, P2TERT+TRAIP. (g) TRAIP is required for optimal RPA2 and H2AX 
phosphorylation in S-phase. P2TERT and P2TERT+TRAIP cells were irradiated with 15 J/m2 UV-C, labeled 
with EdU for 4 h, pre-extracted, fixed and co-stained for pS4/S8-RPA2 or γH2AX, EdU and DAPI. 
Representative images of immunofluorescence staining of pS4/S8-RPA2 (left), quantification of 
pS4/S8-RPA2 (middle) and γH2AX (right) signal integrated density in EdU-positive and EdU-negative 
cells. Mean ± SEM for n=3 experiments, values normalized to P2TERT+TRAIP; Student’s t-test: *p<0.05; 
***p<0.001. Scale bar, 10 µm. 
 
Figure 5. Impaired growth and cell cycle progression in TRAIP deficient cells 
(a) TRAIP mutations impair cell proliferation. Cell numbers of passage-matched primary fibroblast 
cell lines derived from patients or controls were determined over 17 days to establish growth rates. 
Mean ± SEM for n=3 experiments; fold growth relative to day 0. (b) Complementation with wild-type 
TRAIP rescues the slow growth phenotype of TRAIPArg185* cells. P2TERT fibroblasts were reconstituted 
with pMSCV-vector only or pMSCV-TRAIP. Growth rates of passage-matched cell lines were analyzed 
over 18 days. Mean ± SEM for n=3 experiments; fold growth relative to day 0. (c) Doubling times of 
fibroblast cells from (a) and (b). Mean ± SEM for n=3 experiments; Student’s t-test: *p<0.05; 
**p<0.01. (d) TRAIP-depleted cells exhibit delayed S/G2 phase progression. HeLa cells were 
transfected with RNAi against TRAIP or luciferase (Luc) control. 72h later cells were pulse labeled 
with 10 µM BrdU for 30 min before washing out and replacing with fresh media. At indicated times, 
cells were harvested, fixed and prepared for flow cytometry. Left, Western blots of RNAi for TRAIP or 
control Luc demonstrate effective TRAIP depletion. Middle, representative images of gating used in 
analysis of flow cytometry data. Right, quantification of the relative number of cells with 4n content; 
fold change relative to 0h. Mean ± SEM, n=4 experiments. Fold change relative to 0h; two-way 
ANOVA across all time points: ** p<0.01.  
 
Figure 6. Replication fork stalling is increased following UV-induced DNA damage in TRAIP patient 
cells 
(a) First label termination events (representing elevated replication fork stalling) are increased after 
UV irradiation in TRAIP patient fibroblasts. Top left panel, schematic of the experimental plan. 
Bottom left panel, representative images of ongoing or stalled replication forks and new origin firing 
from DNA fiber spreads of primary fibroblasts. Right panel, quantification of ongoing forks, 2nd label 
only (new origin firing) and 1st label termination (fork stalling) structures in fibroblast cells. Mean ± 
SD, n=3 independent experiments, >400 structures per cell line per experiment quantified. Student’s 
t-test: *p<0.05; **p<0.01; ns, not significant. (b, c) Substantial fork asymmetry is seen in UV-treated 
patient cells. (b) Representative images of DNA fibers from controls (Con1, Con2) and patient 
fibroblasts (P2, P3) after 30 J/m2 UV treatment. (c) Quantification of replication fork asymmetry. 
Ratio of left/right fork length; mean ratio for each cell line is indicated in italics; Mann Whitney Rank 
sum test: ***p<0.001; ns, not significant. Data points pooled from n=2 independent experiments, 
>50 structures per cell line per experiment quantified. 
 Table 1. Clinical summary of individuals with TRAIP mutations 
Individual Gender Consanguinity Ancestry Nucleotide 
mutation 
Protein 
alteration 
Gestation 
(weeks) 
BWT 
(kg) 
SD 
Age 
(years) 
Height 
(cm)   
SD 
OFC  
(cm)     
SD 
Karyotype Craniofacial 
features 
Clinical synopsis 
P1 F NC Italian c.553C>T p.Arg185* 37 1.95 
-2.7 
5 85.9 
-5.4 
44 
-6.5 
46, XX Microcephaly, 
scaphocephaly, 
long narrow 
face, 
micrognathia. 
 
IUGR; recurrent severe lower 
respiratory tract infections; 
delayed speech, 2 deceased 
siblings with similar 
phenotypes. 
 
P2 M NC English c.553C>T p.Arg185* 32 1.2 
-2.2 
7 103.5 
-3.9 
40.7 
-8.3 
46, XY Microcephaly, 
scaphocephaly, 
long narrow 
face, 
micrognathia. 
 
IUGR; recurrent severe lower 
respiratory tract infections; 
moderate global 
developmental delay; 
hypertrichosis. 
 
P3 M 3rd cousin Turkish c.52C>T p.Arg18Cys 
 
40 1.75 
-2.9 
3 80 
-4.6 
40.1 
-8.1 
46, XY Microcephaly, 
long narrow 
face, 
micrognathia. 
 
IUGR; asthma; mild global 
developmental delay. 
 
All parents were demonstrated to be heterozygote carriers of the mutations identified, confirming appropriate segregation within the family. Age is shown 
in years at time of measurements. BWT, birth weight; SD, standard deviation from the population mean for age and sex; OFC, occipital frontal 
circumference; F, female; M, male; NC, non-consanguineous; IUGR, intrauterine growth restriction. 
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ONLINE METHODS 
Research subjects 
Genomic DNA from the affected children and family members was extracted from peripheral blood 
using standard methods or saliva samples using Oragene collection kits according to the 
manufacturer’s instructions. Informed consent was obtained from all participating families and the 
studies were approved by the ethics review boards, the Scottish Multicentre Research Ethics 
Committee (04:MRE00/19) and the Ethics Committee of the University Hospital Cologne, Germany. 
Parents provided written consent for the publication of photographs of the affected individuals. 
Exome sequencing and haplotype analysis 
Exome sequencing of genomic DNA and variant filtering was performed as described previously54,55. 
Cohort resequencing was performed by Sanger sequencing of PCR products representing all coding 
exons of TRAIP (primer sequences available on request), with variant calling using MutationSurveyor 
(SoftGenetics Inc). Haplotype analysis was undertaken by SNP genotyping both patients using 
Affymetrix CytoScan 750K arrays. Genotypes were generated using Affymetrix Genotyping Console 
software and examined manually.  
Inbreeding coefficients for P1 and P2 were estimated using FEstim20, using SNP genotypes with 
confidence scores < 10-4, after linkage disequilibrium (LD) pruning using PLINK v1.90b3o (64-bit) 56. 
Runs of homozygosity (ROH) were also used to calculate FROH using PLINK, as described 
previously57,58. In brief, SNPs were excluded with NoCall frequency above 3% across individuals or 
with a minor allele frequency (MAF) < 5%. ROH were defined as runs of at least 50 consecutive 
homozygous SNPs spanning at least 1.5 Mb, with less than a 1 Mb gap between adjacent ROHs and a 
density of SNP coverage within the ROH of no more than 50 Kb/SNP, with at most one heterozygous 
SNP and five NoCalls allowed per window.  
Cell culture 
Lymphoblastoid cell lines (LCLs) were maintained in RPMI 1640 supplemented with 15% fetal bovine 
serum, L-glutamine and penicillin/streptomycin antibiotics in 5% CO2 and normoxic conditions. 
Lymphoblastoid cell lines were generated in house from peripheral blood samples by EBV 
transformation using standard methods. Dermal primary fibroblasts were grown from skin punch 
biopsies in AmnioMax medium (Life Technologies) and then maintained in Dulbecco’s MEM 
(modified Eagle’s medium; DMEM) supplemented with 10% fetal bovine serum, 5% L-glutamine and 
5% penicillin/streptomycin antibiotics in 5% CO2 and hypoxic 3% O2 conditions. Patient cell lines 
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were validated using Sanger sequencing and immunoblotting. HeLa cells were maintained in DMEM 
supplemented with 10% fetal bovine serum, 5% L-glutamine and 5% penicillin/streptomycin 
antibiotics in 5% CO2 and normoxic conditions. HeLa (ATCC), U2OS and MRC5 (GDSC, Sussex) cells 
were cultured in DMEM supplemented with 10% fetal bovine serum, 5% L-glutamine and 5% 
penicillin/streptomycin antibiotics. 
Stable cell lines were generated by Flp recombinase-mediated integration using HeLa-Flp-In T-REx 
host cells (gift from Stephen Taylor, University of Manchester42) transfected with pcDNA5/FRT/TO-
EGFP (vector only or EGFP-TRAIP) and pCAGGS-Flp.e (gift from Dirk-Jan Kleinjan, University of 
Edinburgh). Transfected cells were selected using 5 μg/ml blasticidin and 400 μg/ml hygromycin and 
the resulting colonies were then expanded for testing. Protein expression was induced with 1 μg/ml 
tetracycline treatment. HeLa cells expressing RFP-PCNA were a gift from Agata Lichawska and Jörg 
Mansfeld, Gurdon Institute. Primary fibroblasts derived from P2 were immortalized with hTERT 
retroviral supernatant with 4 μg/ml polybrene and infected with pMSCV-vector only or pMSCV-
TRAIP. Selection was performed using 750 ng/ml puromycin and 500 μg/ml neomycin. Expression of 
the protein was verified by Western blot (Supplementary Fig. 6c). All cell lines were routinely tested 
for mycoplasma. 
Cell treatments 
Plasmids and siRNA oligos were transfected in Opti-MEM reduced serum media using 
Oligofectamine (Life Technologies) according to the manufacturer’s guidelines. The siRNA 
oligonucleotide sequences are listed in Supplementary Table 1a. Where indicated, cells were treated 
with 10 μM MG132 (Cayman Chemicals), 10 or 15 J/m2 UV-C, 2 mM hydroxyurea (Sigma-Aldrich), 0.5 
µM aphidicolin (Sigma-Aldrich), 50 ng/ml mitomycin C (Sigma-Aldrich) or 2 mM thymidine (Sigma-
Aldrich).  
RT-PCR 
Total RNA was extracted from cell lines using the RNeasy kit (Qiagen) according to the 
manufacturer’s instructions. DNA was removed by treatment with DNase I (Qiagen) and cDNA was 
generated using random oligomer primers and AMV RT (Roche). The RT-PCR primer pairs used are 
listed in Supplementary Table 1b.  
Western blot analysis and antibodies 
Whole cell extracts were obtained by lysis and sonication of cells in UTB buffer (8 M Urea, 50 mM 
Tris pH 7.5, 150 mM β-mercaptoethanol, protease inhibitor cocktail (Roche)) or in NP-40 lysis buffer 
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(50 mM Tris pH 8.0, 280 mM NaCl, 0.5% NP-40, 0.2 mM EDTA, 0.2 mM EGTA, 10% Glycerol, 1 mM 
DTT, protease inhibitor cocktail (Roche), 1 mM PMSF, phosphatase inhibitors (40 mM NaF, 1 mM 
sodium orthovanadate)) and analyzed by SDS-PAGE following standard procedures. Protein samples 
were run on 6-12% acrylamide SDS-PAGE or 4-12% NuPage mini-gels (Life Technologies) and 
transferred onto nitrocellulose membrane. Immunoblotting was performed using antibodies to RPA2 
(Santa Cruz, sc-28709; 1:1000), pS4/S8-RPA2 (Bethyl Laboratories, A300-245A; 1:1000), pS33-RPA2 
(Bethyl Laboratories, A300-246A; 1:1000), H2A (Millipore, 07-146; 1:5000), γH2AX (Millipore, 05-
636; 1:1000), actin (Sigma-Aldrich, A2066; 1:5000), vinculin (Sigma-Aldrich, V9264; 1:1000), pS966-
SMC1 (Bethyl Laboratories, A300-050A; 1:1000), SMC1 (Abcam, ab9262; 1:2000), pS343-NBS1 (Cell 
Signaling Technology, 3001; 1:500), NBS1 (Oncogene, PC269T; 1:500), pS345-CHK1 (Cell Signaling 
Technology, 2341; 1:500), CHK1 (Santa Cruz, sc-8408; 1:1000), pT68-CHK2 (Cell Signaling, 2661; 
1:500) , CHK2 (Santa Cruz, sc-9064; 1:500), pS1981-ATM (Cell Signaling, 4526; 1:500), ATM (Abcam, 
ab31842; 1:1000), pS2056-DNA-PKcs (Abcam, ab18192; 1:400), DNA-PKcs (Abcam, ab32566; 
1:1000), pS824-KAP1 (Bethyl Laboratories, A300-767A; 1:5000), KAP1 (Bethyl Laboratories, A300-
274A; 1:10000), CDK1 (Sigma-Aldrich, P7962; 1:1000), cyclin A (Santa Cruz, sc-751; 1:1000), cyclin B1 
(Cell Signaling Technology, 4135; 1:1000), pS10-Histone H3 (Millipore, 06-570; 1:1000), Histone H3 
(Millipore, 07-690; 1:10,000), FLAG (Agilent, clone M2; 1:1000). 
TRAIP antibody was generated from recombinant TRAIP protein using pGEX-4T-2-TRIP-N (gift from 
Robert Geahlen, Purdue University, USA). Antibody was affinity purified from rabbit sera 
(Eurogentec) and specificity established using patient cell lysates and RNAi. 
Laser line assay 
Laser micro-irradiation and live cell imaging were performed as described previously in supplemental 
methods of ref59. Plasmids were transfected into U2OS cells using TransIT-LT1 (Mirus Bio), according 
to the manufacturer’s instructions. Images were acquired using an Olympus FluoView 1000 confocal 
microscope.  
Immunofluorescence: GFP-TRAIP localisation  
MRC5 fibroblasts were transfected with EGFP-TRAIP using Lipofectamine 2000 (Life Technologies) 
according to the manufacturer’s instructions. The cells were trypsinised and seeded onto coverslips 
6 hours post-transfection. The following day, the cells were washed once in warm PBS and treated 
with 2 mM hydroxyurea for 24 h or irradiated either at 25 J/m2 for global UV-C irradiation (fluency 
rate 0.8 J/m2/s) or at 120 J/m2 for local UV-C irradiation through isopore membrane 3 μM filters 
(Millipore) and fixed 1 h or 1.5 h post UV-C, respectively. Immunofluorescence (IF) was performed as 
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previously described60 with minor modifications. Briefly, the cells were either pre-extracted in 
CSK100 buffer and then fixed in 4% paraformaldehyde for 15 min at room temperature or fixed first 
and then permeabilized in 0.5% Triton-X100 in PBS at room temperature for 15 min. Primary and 
secondary antibodies' incubations were performed in IF buffer (3% BSA in PBS) for 1 hour at room 
temperature. Primary antibodies: XPC (Santa Cruz, 1:100), PCNA (PC10, Santa Cruz, 1:400), γH2AX 
(Millipore, 1:500), RPA2 (Calbiochem, 1:200); secondary antibodies: Alexa Fluor-594 or Alexa Fluor-
488 (Molecular Probes); DAPI 0.4 μg/ml (Vectashield). For EdU detection, cells were pulsed with 20 
µM EdU for 20 min and then detected using the Click-iT EdU Imaging kit (Life Technologies) 
according to the manufacturer’s protocol. Fluorescence images were taken using a Nikon E600 
Eclipse microscope equipped with a 60X oil lens, and images were acquired and analysed using 
Volocity Software v4.1 (Improvision). 
Proximity ligation assay (PLA)  
Cells from stable EGFP/ EGFP-TRAIP HeLa Flp-In T-REx cell lines were fixed with methanol at -20 °C 
for 10 min followed by a 5 min extraction in 0.3% Triton-X100 in PBS. Cells were then incubated in 
anti-PCNA antibody (Santa Cruz, PC10; 1:500) and anti-GFP antibody (Abcam, ab6556; 1:500), and in 
situ proximity ligation was performed using a Duolink Detection Kit in combination with anti-Mouse 
PLUS and anti-Rabbit MINUS PLA Probes, according to the manufacturer’s instructions (Sigma Aldrich 
Duolink). Nuclear foci were imaged using a Nikon E600 Eclipse microscope equipped with a 60X oil 
lens, and images were acquired and analysed using Volocity Software v4.1 (Improvision).  The 
number of nuclear foci/cell was quantified using ImageJ. More than 50 cells were analyzed per 
experiment per condition.  
Quantitative immunofluorescence of pSer4/Ser8-RPA2 and γH2AX 
Passage-matched TERT-immortalized fibroblasts were seeded on coverslips, 24 h later damaged with 
15 J/m2 UV-C irradiation and left to recover for 4 hours in media containing 10 µM EdU. To remove 
soluble proteins prior to immunofluorescence, cells were pre-extracted for 10 min on ice with ice-
cold buffer (25 mM Hepes 7.4, 50 mM NaCl, 1mM EDTA, 3 mM MgCl2, 300 mM sucrose and 0.5% 
TritonX-100) and then fixed with 4% paraformaldehyde for 15 min. EdU immunolabeling was 
performed using Click-iT EdU Imaging Kit (Invitrogen, C10337) according to the manufacturer’s 
protocol. Afterwards cells were stained for pS4/S8-RPA2 (Bethyl Laboratories, A300-245A; 1:1000) or 
γH2AX (Millipore, 05-636; 1:800) and then stained with secondary antibodies conjugated to Alexa 
Fluor-568 (Life Technologies) and DAPI. For quantification of signal integrated densities, images were 
visualized using a Zeiss Axioplan 2 microscope with iVision software (BioVision Technologies) and 
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captured using 40X oil-immersion objective. Exposure time, binning, microscope settings and light 
source intensity were kept constant for all the samples. Nuclei were segmented on the basis of DAPI 
staining and then signal integrated density of pS4/S8-RPA2 and γH2AX staining quantified for each 
nuclear region using ImageJ software (US National Institutes of Health). More than 50 EdU positive 
and 150 EdU negative cells were analyzed per experiment per condition.  
Comet assay  
Neutral comet assays were carried out using the Trevigen Comet Assay™ electrophoresis kit (4250-
050-K) according to manufacturer’s instructions. Briefly, 1x105 primary fibroblasts were seeded in 6 
well plates overnight for approximately 16 hours.  Cells were then treated with 15 J/m2 UV-C and 
allowed to recover for 4 hours in media.  Cells were collected and embedded into low melting 
agarose on 'comet' slides (Trevigen) and incubated in lysis solution overnight in the dark at 4°C.  Cells 
were then electrophoresed in buffer (50 mM Tris pH 9.0, 150 mM sodium acetate) for 45 min at 21 
volts at 4°C in the dark.  Comet slides were immersed in DNA precipitation solution (1 M ammonium 
acetate, 95% ethanol) for 30 min and 70% ethanol for 30 min at room temperature and dried at 37°C 
for 15 min. Slides were stained in 1x SYBR gold in TE buffer (pH 7.5) for 30 min at room temperature, 
dried for an additional 15 min at 37°C and then visualized with an epifluorescence microscope and 
analyzed using CaspLab software.  
FACS analysis 
Passage-matched TERT-immortalized fibroblasts grown in AmnioMax medium (Life Technologies) or 
HeLa cells were pulse labeled with 10 μM BrdU for 30 min before fixation with 70% ethanol at -20°C 
for 16 h. Cells were then digested with 1 mg/ml pepsin and denatured with 2 M HCl, before washing 
with PBS and blocking in 0.5% BSA, 0.5% Tween-20. BrdU labeling was detected using anti-BrdU 
antibody (Abcam, ab6326; 1:75) and FITC-conjugated anti-rat secondary antibody. DNA content was 
assessed by staining with 50 μg/ml propidium iodide. Cells were sorted on a BD Biosciences FACS 
Aria II and data were analyzed using FlowJo software (v7.6.1, Tree Star). 
Mitotic index of pulse labeled EdU cells 
HeLa cells were seeded on poly-L-lysine-coated coverslips 48 h after siRNA transfection. The 
following day, 10 µM EdU was added to the cells for 30 min, washed out with PBS and media 
replaced. 6 h later cells were fixed using 4% paraformaldehyde and stained for pSer10-Histone H3 
(Cell Signalling, 9706; 1:250) and EdU (Click-iT EdU Imaging Kit, Invitrogen, C10337) according to the 
manufacturer’s protocol. Cells were then stained with secondary antibody conjugated to Alexa 
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Fluor-568 (Life Technologies) and analyzed using a Zeiss Axioplan 2 microscope equipped with a 60X 
oil-immersion objectives and iVision software (BioVision Technologies). 
G2/M checkpoint assay 
A previously established assay was used to determine mitotic cell number after damage-induced 
checkpoint activation61. In brief, HeLa cells transfected with RNAi against TRAIP or luciferase 
(control) for 72 h were treated with 10 J/m2 UV-C and fixed in 96% ethanol 4 h later. Mitotic cells 
were determined by pSer10-Histone H3 (Cell Signalling, 9706; 1:250) staining and flow cytometry on 
a BD Biosciences FACS Aria II.  
DNA fiber spreading assay 
Passage-matched primary or TERT-immortalized fibroblasts were pulse labeled with CldU for 20 min, 
washed with PBS and damaged with 30 J/m2 UV-C, 2 mM hydroxyurea for 2 h or 0.5 µM aphidicolin 
before being pulse labeled with IdU for 20 or 40 min as indicated. 0.5 µM aphidicolin was added to 
the cells for 40 min together with IdU pulse labeling. 50 ng/ml mitomycin C was added to the cells 
for 24 h before CldU pulse labeling and left on during 20 min CldU and 20 min ldU pulse labeling. 
Cells were harvested by trypsinization and cell pellets were washed in PBS. 5x105 cells were lysed 
directly onto glass slides using spreading buffer (200 mM Tris-HCl pH 7.5, 50 mM EDTA, 0.5% SDS) 
and fixed in methanol:acetic acid (3:1 ratio). Following 2.5 M HCl denaturation, CldU was detected 
using rat anti-BrdU (clone BU1/75, ICR1; Abcam, ab6326; 1:750) and IdU was detected using mouse 
anti-BrdU (clone B44; BD Biosciences, 347583; 1:750). Slides were then fixed in 4% 
paraformaldehyde before immunostaining with secondary antibodies conjugated to Alexa Fluor-594 
or Alexa Fluor-488 (Life Technologies). Labeled DNA fibers were visualized using a Zeiss Axioplan 2 
microscope with iVision software (BioVision Technologies). Images were captured using 40X oil-
immersion objectives and analyzed using ImageJ software (US National Institutes of Health). 
In vitro transcription/translation 
The TnT® T7 Quick Coupled Transcription/Translation System (Promega) was used to produce FLAG-
tagged TRAIP (WT, R18C or R185X) in vitro following the manufacturer’s instructions. Briefly, 250 ng 
of plasmid DNA (pcDNA-based, TRAIP with an N-terminal single FLAG epitope) in 2.25 µl of water 
was mixed with 10 µl TNT® T7 Quick Master Mix, 0.25 µl of 1 mM methionine and incubated for 90 
min at 30°C. For immunoblotting 1 µl of each reaction was separated by SDS-PAGE on 4-12% 
NuPAGE gels (Life Technologies), and TRAIP was detected using anti-FLAG or anti-TRAIP antibodies. 
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Statistical analysis 
Numerical data were analyzed using parametric and nonparametric statistical tests, namely 
Student’s t-test, ANOVA or Mann Whitney Rank sum test, as indicated. Statistical tests were two-
sided unless otherwise stated in figure legend. Significance thresholds are indicated in figure 
legends. 
 
METHODS-ONLY REFERENCES 
54. Martin, C.A. et al. Mutations in PLK4, encoding a master regulator of centriole biogenesis, 
cause microcephaly, growth failure and retinopathy. Nat Genet 46, 1283-1292 (2014). 
55. Keupp, K. et al. Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet 
92, 565-574 (2013). 
56. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based 
linkage analyses. Am J Hum Genet 81, 559-575 (2007). 
57. Joshi, P.K. et al. Directional dominance on stature and cognition in diverse human 
populations. Nature 523, 459-462 (2015). 
58. McQuillan, R. et al. Runs of homozygosity in European populations. Am J Hum Genet 83, 359-
372 (2008). 
59. Polo, S.E. et al. Regulation of DNA-end resection by hnRNPU-like proteins promotes DNA 
double-strand break signaling and repair. Mol Cell 45, 505-516 (2012). 
60. Despras, E., Delrieu, N., Garandeau, C., Ahmed-Seghir, S. & Kannouche, P.L. Regulation of the 
specialized DNA polymerase eta: revisiting the biological relevance of its PCNA- and 
ubiquitin-binding motifs. Environ Mol Mutagen 53, 752-765 (2012). 
61. Stewart, G.S., Wang, B., Bignell, C.R., Taylor, A.M. & Elledge, S.J. MDC1 is a mediator of the 
mammalian DNA damage checkpoint. Nature 421, 961-966 (2003). 
 






 
 
Supplementary Figure 1 
Patients P1 and P2 have distant common ancestry, sharing a common 4.3 Mb homozygous haplotype across the TRAIP locus 
(a) Schematic of high density SNP genotyping of the TRAIP locus in P1 and P2 (blue shading) demonstrates that both patients have 
4.6 Mb and 8.4 Mb regions of homozygosity surround the TRAIP gene which lies at 49.9 Mb. An identical haplotype of 117 SNPs is 
 
 
evident in both patients within the shared region of homozygosity consistent with a shared common ancestor. Heterozygous SNP 
markers delineating regions of homozygosity are shown in red. 102 homozygous SNP markers within the 4.3 Mb region are omitted for 
clarity. (b) Inbreeding coefficients (F) estimates for P1 and P2 from SNP genotype data. FEstim analysis software that utilizes hidden 
Markov chain maximum likelihood estimation approach on the basis of observed genome-wide marker genotypesS3 was used to derive 
inbreeding coefficients for patient P1 and P2  from genome wide SNP genotyping data. An inbreeding coefficient of 0.003 was found for
P2 that corresponds to an inbreeding coefficient seen in offspring of 3rd cousin parents. This estimate was confirmed by a 
complimentary approach that derives a statistic FROH from the percentage of the genome containing large regions of homozygosity, a
measure that correlates well with inbreeding coefficients derived from pedigreesS4. Additionally, two point linkage analysis using the
known family pedigree in P3 and a pedigree equating to the calculated inbreeding coefficient of 0.003 for P2, generates a significant 
combined LOD score of 4.42 at θ=0. 
 
 
 
 
 
 
 
                                                                  
Supplementary Figure 2 
TRAIP protein levels are markedly reduced in patient P2 
Expression of TRAIP protein is only detectable on prolonged exposure of Western blots. Residual protein detected may include the 
isoform encoded by a transcript that skips exon 7. Deletion in this exon results in an in-frame deletion of 37 amino acids, which would 
be predicted to result in a 47 kDa protein that will be difficult to distinguish from the 53 kDa full-length TRAIP on immunoblotting.
Immunoblotting performed on cell lysates using TRAIP and H2A (loading control) antibodies. 
 
 
 
Supplementary Figure 3 
A TRAIP polyclonal antibody raised against recombinant GST-TRAIP aa1-270, detects WT, Arg18Cys and Arg185*-truncated TRAIP 
proteins 
(a) N-terminal FLAG-tagged TRAIP proteins, either WT or with patient mutations, were generated by in vitro transcription/translation 
(IVT) and then immunoblotted with either anti-FLAG or the rabbit polyclonal anti-TRAIP antibody generated in this study. Empty vector 
(-) was used as a negative control. The TRAIP antibody recognized all forms of TRAIP as efficiently as the anti-FLAG antibody, 
including the missense Arg18Cys mutation from patient P3 and the truncated TRAIP protein corresponding to aa1-184 that might be 
translated from transcripts containing the truncating Arg185* mutation in patients P1 and P2. WT and Arg18Cys were present at the 
same level (anti-FLAG) and detected equally well with TRAIP antibody, whereas Arg185* was present at a lower level (anti-FLAG), but 
still detected well with TRAIP antibody. The additional lower molecular band in each lane on the anti-TRAIP antibody blot likely results 
from untagged TRAIP protein generated during in vitro translation through usage of an alternative methionine start site, present
immediately after the FLAG tag. (b) Full Western blots of patients P1 and P2 reveal no short truncated form of TRAIP protein, indicating 
that the mutated transcripts are most likely degraded via nonsense-mediated decay. 
 
 
 
 
 
 
 
 
                                                             
Supplementary Figure 4 
TRAIP transcript levels in patient P3 primary fibroblasts are not depleted 
RT-PCR using primers in 5’ and 3’ UTR to amplify TRAIP mRNA in primary fibroblasts demonstrates similar transcript levels in patient
P3 cells when compared to control fibroblast cell line. Loading control, GAPDH.  
 
 
 
 
 
Supplementary Figure 5 
TRAIP is degraded via the proteasome in response to UV damage 
(a) Immunoblots of control fibroblast cells (upper panel) and HeLa cells (lower panel) treated with UV-C, before harvesting at the 
indicated times. The proteasome inhibitor MG132 (10 µM) was added to cell media at t=0 h. Cell lysates were analyzed by Western blot 
using antibodies against TRAIP and actin or H2A (loading controls). (b) Reduction in TRAIP protein levels is not accounted for by an 
indirect effect on cell cycle, as TRAIP protein levels remain relatively constant through the cell cycle. HeLa cells synchronized at the 
G1/S phase boundary by double thymidine block; time course following release into fresh media. Samples harvested at the indicated 
times and cell lysates analyzed by Western blot using antibodies against TRAIP, CDK1, cyclin A, cyclin B1, pSer10-Histone H3 and 
Histone H3. 
 
 
Supplementary Figure 6 
TRAIP-deficient cells are generally proficient in ATM, DNA-PKcs and ATR signaling in response to UV-C 
(a) TRAIP-depleted HeLa cells are proficient in ATM and DNA-PKcs signaling. HeLa cells were transfected with RNAi against TRAIP or
luciferase (control). After 72h, cells were UV-C treated, before harvesting at indicated times. Cell lysates were analyzed by Western blot
as indicated. (b) Phosphorylation of Ser33-RPA2 is unaffected by TRAIP depletion. HeLa cells transfected with RNAi against TRAIP or
control were UV-C treated and harvested at indicated times. Cell lysates prepared using NP-40-based lysis buffer were analyzed by 
Western blot using antibodies against TRAIP, pSer33-RPA2, RPA2 and Vinculin. (c) TRAIP protein expression is restored in hTERT-
immortalized patient fibroblasts following retroviral complementation with pMSCV-TRAIP. Western blots of patient fibroblasts after 
hTERT immortalization and retroviral transduction of pMSCV-vector only or pMSCV-TRAIP. * denotes a non-specific band. (d) 
Characterization of ATM, DNA-PKcs and ATR activation in P2TERT and P2TERT+TRAIP fibroblasts after UV-C irradiation. P2TERT and 
P2TERT+TRAIP fibroblasts were UV-C treated and harvested at indicated times. Cell lysates were analyzed by Western blot as indicated.
ATM and DNA-PKcs autophosphorylation and NBS1 and KAP1 phosphorylation were similar in both cell lines, while a small reduction
in CHK1 phosphorylation was observed in P2TERT cells. (e) TRAIP-depleted HeLa cells are proficient in G2/M checkpoint assay. Mitotic
index is unchanged in TRAIP-depleted HeLa cells (plotted relative to the mitotic index of untreated cells in the same experiment). Mean
± SEM; n=3 independent experiments. 
 
 
Supplementary Figure 7 
TRAIP promotes S-phase specific RPA2 and H2AX phosphorylation induced by UV-C  
(a, b) Scatter plots represent pSer4/Ser8-RPA2 (a) or γH2AX (b) signal integrated densities (arbitrary units) of individual EdU-negative 
and EdU-positive P2TERT and P2TERT+TRAIP fibroblasts shown in Figure 4g. Red lines denote mean ± SEM for n=3 independent
experiments. Pooled data plotted, n>50 EdU positive cells and n>150 EdU negative cells quantified per cell line per treatment per
experiment. 
 
 
 
 
 
 
Supplementary Figure 8 
TRAIP mutations do not detectably alter the accumulation of DNA strand breaks following UV-C treatment 
Primary patient fibroblasts or controls were UV-C treated and harvested 4 h later for neutral comet assay. Graph represents 
quantification of mean olive tail moments ± SEM for n=4 independent experiments. >250 comets analyzed per cell line per treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 9 
TRAIP-deficiency delays cell cycle progression in S/G2 
(a) Quantification of number of mitotic cells contributing to 4n cell number at 6 h in Figure 5d. The mitotic index of siTRAIP EdU positive 
cells 6 h after EdU pulse labeling is not significantly different from control siRNA treated cells. Mean ± SEM of n=3 independent 
experiments; >800 EdU positive cells quantified per experiment. (b, c) Complementation with TRAIP restores delayed S/G2 phase 
progression of P2TERT fibroblasts. P2TERT and P2TERT+TRAIP cells were labeled with 10 µM BrdU for 30 min before washing out and
replacing with fresh media. At indicated times, cells were harvested, fixed and prepared for flow cytometry. (b) Representative images 
of gating used in analysis of flow cytometry data. (c) Quantification of BrdU positive cells at 0, 4 and 8 h after BrdU pulse labeling. Left,
percentage of cells with 2n content; middle, percentage of cells with mid S phase content; right, percentage of cells with 4n content. 
Mean ± SEM of n=4 independent experiments; for 8 h time point, Student’s t-test: *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 10 
Fork velocity, inter-origin distance and new origin synthesis rates are unaltered in TRAIP patient primary fibroblasts 
(a) Top panel, schematic indicating DNA labeling protocol. Bottom panel, quantification of IdU tract lengths in control and patient 
fibroblasts. Mean ± SEM of n=3 independent experiments; >100 fibers measured per cell line per experiment. (b) Quantification of inter-
origin distances. Box plots, center lines indicate mean, box 25/75% and whiskers 5/95%. n=3 independent experiments; >30 structures 
measured per cell line per experiment. (c) Quantification of ongoing forks, 2nd label only (new origin firing) and 1st label termination 
(fork stalling) structures. Mean ± SD, n=3 independent experiments; > 300 fibers measured per cell line per experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 11 
Complementation with wild-type TRAIP rescues increased fork stalling and fork asymmetry in UV-irradiated TRAIPArg185* cells 
(a) Fork velocities in UV-treated TRAIP patient primary fibroblasts are similar to wild-type control cells. Mean ± SEM, n=2 independent
experiments, >100 structures measured per cell line per experiment. (b) Quantification of ongoing forks, 2nd label only (new origin 
 
 
firing) and 1st label termination (fork stalling) structures, untreated or after 30 J/m2 UV-C irradiation. Mean ± SD, n=3 independent 
experiments. >400 structures measured per cell line per experiment. Student’s t-test: **p<0.01; ns, not significant. (c) Quantification of 
replication fork asymmetry in P2TERT and P2TERT+TRAIP fibroblasts after 30 J/m2 UV, 0.5 µM aphidicolin or 50 ng/ml mitomycin C 
treatment. Ratio of left/right fork length; mean ratio for each cell line is indicated in italics; Mann Whitney Rank sum test: ***p<0.001; ns, 
not significant. Data plotted pooled from n=2 independent experiments, with >50 structures quantitated per cell line per experiment. (d) 
Quantification of ongoing forks, 2nd label only (new origin firing) and 1st label termination (stalled fork) structures, untreated or after 50
ng/ml mitomycin C treatment. (e) Track lengths are not detectably altered in TRAIP-deficient fibroblasts compared with controls, after 
UV-C or low dose aphidicolin treatment.  P2TERT and P2TERT+TRAIP fibroblasts untreated or following treatment with 30 J/m2 UV or 0.5 µM 
aphidicolin. Mean ± SEM, n=2 independent experiments. >100 tracts measured per cell line per experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 12 
Replication restart is not impaired in TRAIP patient cells after hydroxyurea-induced fork arrest 
Top, schematic of the experiment. Bottom, quantification of ongoing forks, 2nd label only (new origin firing) and 1st label termination 
(fork stalling) structures. Data are mean ± SD for n=2 independent experiments. >300 structures quantified per cell line per experiment.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 13 
Model: Impaired DNA damage response to replication blocking lesions such as UV photodimers in TRAIP patient cells can reduce
growth through reduction in cell number generated during development 
Replication blocking lesions (red circles) arise in the genome during development, which require efficient DDR for their resolution and to 
ensure efficient cellular proliferation utilizing multiple repair pathways that include translesion synthesis/post-replication repair. In TRAIP 
patient cells, impaired DDR during replication results in delayed S/G2 phase progression. Increased cell cycle length and reduced 
numbers of cycling cells will consequently lead to reduction in overall cell proliferation, decreasing total cell number. Impaired spindle 
checkpoint function could also increase aneuploidy levels leading to increased cell deathS5. However, unlike mutations in BUBR1S6, an 
archetypal SAC protein, variegate aneuploidy is not observed with normal karyotypes in all TRAIP patients (Table 1). Decrease in cell 
number results in diminished growth potential, with reduction in both brain and body size. 
 
 
 
 
Supplementary Note. Summary of clinical phenotypes 
All patients had IUGR (birth weight ranging from -2.2 to -2.9 SD) and postnatally substantially 
reduced height (range -3.9 to -5.4 SD) with disproportionate microcephaly (range -6.5 to -8.3 SD). 
Growth parameters were therefore consistent with microcephalic primordial dwarfism, particularly 
with that seen within the primary microcephaly-Seckel syndrome spectrumS1. In addition, P1 had 
two siblings with IUGR, microcephaly and facial features consistent with Seckel syndrome, both of 
whom died in early infancy as a result of respiratory failure. The clinical features of these siblings 
have been previously reportedS2; however DNA was not available to confirm the presence of TRAIP 
mutations in these two siblings. 
 
All three individuals had similar phenotypic features with long narrow faces, micrognathia and 
prominent ears. P1 and P2 additionally had scaphocephaly. Mild-moderate developmental delay was 
present in all. In P2 and P3, neuroimaging demonstrated reduced cerebral cortical size, without 
thickening of the cortex, consistent with ‘microcephaly with simplified gyri’ in P2 and P3.  In P1, a 
small cyst between the anterior and posterior pituitary and a slightly enlarged ventricular system 
were noted. 
 
P1 and P2 experienced frequent lower respiratory tract infections. These required multiple intensive 
care admissions for P2, with respiratory syncytial infection specifically identified in one such 
admission. P1 and P2 both had chronic chest X-ray changes; chest CT showing atelectasis with 
mediastinal shift in P1. Medical management of P2 included prophylactic antibiotics. Respiratory 
care of P1 included regular chest physiotherapy, inhaled corticosteroid treatment and prophylactic 
antibiotics. This patient passed away secondary to acute respiratory failure aged 8 years. A diagnosis 
of asthma has been made for P3 who also has a history of recurrent urinary tract infections. Aside 
from a mild lymphopenia, not thought to be of clinical significance in P2, no evidence of 
immunodeficiency was detected in any of the patients.  All patients had normal immunoglobulin 
levels.  
 
Karyotypes from P1-P3 were reported as normal.  A trial of GH in P1 did not lead to increased growth 
velocity. 
 
 
 
 
 
 
 
 
 
 Supplementary Table 1. Primer sequences related to experimental procedures 
 
a) siRNA oligonucleotide sequences 
Name 
siTRAIP-524 AGCAGAUGAAGUACUUAGA[dT][dT] 
siLuciferase CUUACGCUGAGUACUUCGA[dT][dT] 
b) RT-PCR primer sequences 
Name Forward sequence Reverse sequence 
TRAIP-5’UTR and -3'UTR CCTTGAGTCCAGCCATCATGCCTATCC GGCCATTGGTCAGACTCACTGTTC 
GAPDH GGACTCCACGACGTACTCAGCGCCAGC GTGGATATTGTTGCCATCAATGACC 
 
 
 
 Supplementary References 
 
S1. Verloes, A., Drunat, S., Gressens, P. & Passemard, S. Primary Autosomal Recessive 
Microcephalies and Seckel Syndrome Spectrum Disorders. in GeneReviews(R) (eds. Pagon, 
R.A. et al.) (Seattle (WA), 1993). 
S2. Silengo, M., Del Monaco, A., Linari, A. & Lala, R. Low birth-weight, microcephalic 
malformation syndrome in a 46,XX girl and her 46,XY sister with agonadism: third report of 
the Kennerknecht syndrome or autosomal recessive Seckel-like syndrome with previously 
undescribed genital anomalies. Am J Med Genet 101, 275-278 (2001). 
S3. Leutenegger, A.L. et al. Using genomic inbreeding coefficient estimates for homozygosity 
mapping of rare recessive traits: application to Taybi-Linder syndrome. Am J Hum Genet 79, 
62-66 (2006). 
S4. McQuillan, R. et al. Runs of homozygosity in European populations. Am J Hum Genet 83, 359-
372 (2008). 
S5. Chapard, C. et al. The TRAF-interacting protein (TRAIP) is a regulator of the spindle assembly 
checkpoint. J Cell Sci 127, 5149-5156 (2014). 
S6. Hanks, S. et al. Constitutional aneuploidy and cancer predisposition caused by biallelic 
mutations in BUB1B. Nat Genet 36, 1159-1161 (2004). 
 
 
